Therapeutic Goods (Medicines—Hydroxychloroquine and Chloroquine) (COVID-19 Emergency) Exemption 2020

Administered by Department of Health, Disability and Ageing

Legislation au F2020N00041 Not in force Notifiable Instrument

Legislation content

 

Therapeutic Goods (Medicines—Hydroxychloroquine and Chloroquine) (COVID-19 Emergency) Exemption 2020

I, Caroline Edwards, as delegate of the Minister for Health, make the following exemption.

Dated 2 April 2020

Caroline Edwards

Acting Secretary

Department of Health

 

Contents

1  Name

2  Commencement

3  Authority

4  Definitions

5  Exemption

6  Conditions

 

 

1  Name

  This instrument is the Therapeutic Goods (MedicinesHydroxychloroquine and Chloroquine) (COVID-19 Emergency) Exemption 2020.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

The day this instrument is made.

2 April 2020

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under section 18A of the Therapeutic Goods Act 1989.

4  Definitions

Note: A number of expressions used in this instrument are defined in section 3 of the Act, including the following:

  1.       manufacture;
  2.       medicine;

(c) supply.

  In this instrument:

Act means the Therapeutic Goods Act 1989.

COVID-19 emergency means the public health emergency caused by the outbreak of the disease known as coronavirus disease (COVID-19).

Note: The World Health Organization declared the outbreak of COVID-19, formerly novel coronavirus (2019 nCoV), a Public Health Emergency of International Concern on 30 January 2020, and subsequently characterised the outbreak as a pandemic on 11 March 2020. On 18 March 2020, the Australian Government declared a human biosecurity emergency in Australia under the Biosecurity Act 2015.

Regulations means the Therapeutic Goods Regulations 1990.

specified therapeutic goods means a medicine to which each of the following paragraphs apply:

 (a) the medicine contains the active ingredient, hydroxychloroquine sulfate or chloroquine phosphate; and

 (b) the medicine does not contain any other active ingredient; and

 (c) the medicine is manufactured in appropriate dosage forms for oral administration.

5  Exemption

 (1) The specified therapeutic goods are exempt from the operation of Division 2 of Part 3-2 of the Act in order to deal with the actual threat to public health caused by the COVID-19 emergency.

Note: Under paragraph 18A(2)(b) of the Act, the Minister may make an exemption under subsection 18A(1) only if satisfied that, in the national interest, the exemption should be made so that the goods can be made available urgently in Australia to deal with an actual threat to public health caused by an emergency that has occurred.

Period of exemption

 (2) This exemption takes effect on the commencement of this instrument and ceases to have effect on 31 January 2021.

6  Conditions

  This exemption is subject to the following conditions:

  1.     the specified therapeutic goods must only be imported, exported, manufactured or supplied by:

 (i) a person under a contract between the person and the Australian Government Department of Health for that purpose; or

 (ii) a person who has made prior written arrangement with the Australian Government Department of Health for that purpose; and

  1.     the specified therapeutic goods must only be supplied in Australia for the prevention, treatment or alleviation of coronavirus disease (COVID-19) following advice from the Australian Government Department of Health; and
  2.     the supply of the specified therapeutic goods for a therapeutic use mentioned in paragraph (b) must be accompanied by a patient information leaflet (in hard copy or electronic form) that includes the information specified in Schedule 1 relating to the therapeutic use; and
  3.     the patient information leaflet mentioned in paragraph (c) must be supplied in a manner that ensures the information is given to the person to whom the goods are administered or otherwise dispensed; and

 (e) the person mentioned in paragraph (a) must keep records in relation to the importation, exportation, manufacture and supply of the relevant specified therapeutic goods; and

 (f) on request from the Secretary, the person mentioned in paragraph (a) must make the records mentioned in paragraph (e) available to the Secretary; and

 (g) the specified therapeutic goods must be stored and transported in a manner that ensures:

 (i) the security of the goods is appropriate to the level of risk that the goods pose to the public and environment; and

 (ii) the integrity of the condition of the goods is maintained.

Note 1: There are offences and civil penalty provisions in relation to goods exempt under section 18A, including:

(a) sections 20, 22 and 22AA (offences and civil penalties for breaching a condition of exemption);

(b) sections 30F and 30FA (offence and civil penalty for goods not conforming to standards);

(c) section 30H (offence for not keeping records);

(d) sections 35 and 35A (offence and civil penalty for manufacturing goods without a licence).

Note 2: There are other provisions in the Act that apply to goods exempt under section 18A, including:

(a) section 31AA (requirement to provide information to the Secretary);

(b) sections 39 and 41 (provisions relating to manufacturing goods);

(c) section 46A (provision enabling search of premises).

Note 3: Regulation 12AAB and Schedule 5B of the Regulations set out arrangements for the disposal of unused emergency goods for the purposes of section 30G of the Act.


Schedule 1—Patient information leaflet

Note: See section 6.

 

Information to be included in a patient information leaflet

Item

Specified information

1

  1.    the name of the medicine;
  2.    the quantity, proportion or strength of each active ingredient;
  3.    the method of administration;
  4.    the suggested dosage and duration of treatment;
  5.    the suggested frequency of administration;
  6.     a statement that optimal dosage, duration of treatment and frequency of administration is unknown;
  7.    a statement regarding contraindications;
  8.    a statement regarding warnings, precautions and other safety measures including symptoms and recommended treatment of overdose or accidental poisoning;
  9.     a statement regarding the medicine’s interactions with other medicines and other serious forms of interactions;
  10.     a statement regarding adverse or undesirable effects;
  11.    a statement regarding appropriate storage conditions and a reference to the expiry date;
  12.     the name, street address and contact details of the Australian sponsor.

 

Overview

The Therapeutic Goods (Medicines—Hydroxychloroquine and Chloroquine) (COVID-19 Emergency) Exemption 2020 was enacted to provide a temporary exemption for the importation, exportation, manufacture, and supply of hydroxychloroquine sulfate and chloroquine phosphate medicines, which are specifically intended for use in the prevention, treatment, or alleviation of COVID-19. This exemption was introduced in response to the urgent need to address the public health threat posed by the COVID-19 pandemic, and it was made under the authority of section 18A of the Therapeutic Goods Act 1989. The exemption was intended to facilitate the rapid availability of these medicines in Australia to mitigate the impact of the pandemic. The exemption is subject to several conditions, including that the medicines must only be supplied for the specified therapeutic use, and that patient information leaflets must be provided with each supply. The exemption was effective from 2 April 2020 and was set to expire on 31 January 2021, unless otherwise amended.

Scope and Application

The Therapeutic Goods (Medicines—Hydroxychloroquine and Chloroquine) (COVID-19 Emergency) Exemption 2020, made under section 18A of the Therapeutic Goods Act 1989, exempts certain therapeutic goods containing hydroxychloroquine sulfate or chloroquine phosphate from specific sections of the Act in response to the COVID-19 emergency. This exemption applies to medicines that are manufactured in appropriate dosage forms for oral administration and do not contain any other active ingredients. The exemption allows for the importation, exportation, manufacture, and supply of these specified therapeutic goods by entities under contract with or having prior written arrangements with the Australian Government Department of Health, provided they are used for the prevention, treatment, or alleviation of COVID-19. The exemption is contingent on strict conditions, including the requirement for a patient information leaflet to accompany the goods and the maintenance of detailed records. This exemption, which commenced on 2 April 2020 and will cease on 31 January 2021, is subject to various offences and civil penalty provisions, as well as other regulatory requirements outlined in the Act and Regulations.

Key Provisions

The Therapeutic Goods (Medicines—Hydroxychloroquine and Chloroquine) (COVID-19 Emergency) Exemption 2020 is an instrument made under section 18A of the Therapeutic Goods Act 1989. It aims to address the actual threat to public health caused by the COVID-19 emergency. This exemption exempts specified therapeutic goods, which include medicines containing hydroxychloroquine sulfate or chloroquine phosphate but no other active ingredients, and are manufactured in appropriate dosage forms for oral administration, from certain requirements of the Act. This exemption came into effect on 2 April 2020 and will cease to have effect on 31 January 2021. The Act imposes several obligations and requirements on the parties or entities it governs. Firstly, the specified therapeutic goods must only be imported, exported, manufactured, or supplied by a person under a contract with the Australian Government Department of Health or by a person who has made prior written arrangements with the Department of Health for that purpose. Secondly, the specified therapeutic goods must only be supplied in Australia for the prevention, treatment, or alleviation of COVID-19 following advice from the Department of Health. Thirdly, any supply of the specified therapeutic goods for a therapeutic use must be accompanied by a patient information leaflet (in hard copy or electronic form) that includes specific information such as the name of the medicine, the quantity, proportion, or strength of each active ingredient, the method of administration, and other specified information. Fourthly, the person responsible for the importation, exportation, manufacture, and supply of the specified therapeutic goods must keep records in relation to these activities and make them available to the Secretary upon request. Lastly, the specified therapeutic goods must be stored and transported in a manner that ensures their security and maintains their integrity. Failure to comply with the conditions of the exemption or any of the other provisions of the Act may result in criminal or civil penalties. For instance, sections 20, 22, and 22AA of the Act provide for offences and civil penalties for breaching a condition of exemption. Similarly, sections 30F and 30FA provide for an offence and civil penalty for goods not conforming to standards, while section 30H provides for an offence for not keeping records. Other provisions of the Act, such as sections 35 and 35A, provide for offences and civil penalties for manufacturing goods without a licence. Furthermore, section 31AA requires the person responsible for the importation, exportation, manufacture, and supply of the specified therapeutic goods to provide information to the Secretary, while sections 39 and 41 provide for provisions relating to manufacturing goods. Section 46A enables a search of premises. Additionally, Regulation 12AAB and Schedule 5B of the Therapeutic Goods Regulations 1990 set out arrangements for the disposal of unused emergency goods for the purposes of section 30G of the Act.

Legal classification tags

Area of Law
Public Health Law
Instrument
Notifiable instrument
Concepts
Commencement Provisions
Offence Provisions
Reporting & Disclosure Obligations
Regulatory Standards
Catchwords
COVID-19 emergency

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.